Pruritis

Also known as: Pruritus / Itch / Pruritus NOS / Itching / Unspecified pruritic disorder / Pruritus cutaneous / Itchy skin / Itchy

DrugDrug NameDrug Description
DB01246AlimemazineA phenothiazine derivative that is used as an antipruritic.
DB00288AmcinonideAmcinonide is a corticosteroid.
DB01432CholestyramineCholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
DB01047FluocinonideA topical glucocorticoid used in the treatment of eczema.
DB14512Mometasone furoateMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295]. It has a glucocorticoid receptor binding affinity 22 times stronger than [dexamethasone] and higher than many other corticosteroids as well[A176906]. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295].
DB01183NaloxoneNaloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. When taken in large quantities, opioid medications such as morphine, hydromorphone, methadone, heroin, or fentanyl are capable of causing life-threatening symptoms such as respiratory depression, reduced heart rate, slurred speech, drowsiness, and constricted pupils. If untreated, this can progress to vomiting, absent pulse and breathing, loss of consciousness, and even death. Naloxone is indicated for the rapid reversal of these symptoms of central nervous system depression in opioid overdose. It's important to note that naloxone only works on opioid receptors within the body, and is therefore not capable of reversing the effects of non-opioid medications such as stimulants like methamphetamine or cocaine, or benzodiazepines like lorazepam or diazepam. Also known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion. Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained individuals within the community. Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. Frequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction strategies. When injected intramuscularly (IM), naloxone acts within 3-5 minutes and can last from 30-60 minutes before its effects wear off. Administration of naloxone is associated with very few side effects. Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all. However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal symptoms. Common symptoms of opioid withdrawal include nausea, vomiting, sweating, runny nose, aches, and diarrhea. Although certainly physically uncomfortable, opioid withdrawal symptoms are not life-threatening like they are for alcohol withdrawals. Administration of naloxone is therefore appropriate for any person appearing to have any symptoms of an opioid overdose. Due to its short duration of action, person's injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. Naloxone is also available within the combination product Suboxone with the opioid medication buprenorphine. Suboxone is used for the maintentance treatment of opioid dependence and addiction. When taken orally, naloxone has no pharmacological effect and does not reduce the effectiveness of the opioid effect of buprenorphine. The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.
DB11614RupatadineRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use.
DB00596UlobetasolUlobetasol (as ulobetasol propionate) is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DrugDrug NameTargetType
DB01246AlimemazineHistamine H1 receptortarget
DB01246AlimemazineCytochrome P450 3A4enzyme
DB00288AmcinonideGlucocorticoid receptortarget
DB00288AmcinonideAnnexin A1target
DB00288AmcinonideCytochrome P450 3A4enzyme
DB01432CholestyramineBile acidstarget
DB01047FluocinonideCorticosteroid-binding globulincarrier
DB01047FluocinonideGlucocorticoid receptortarget
DB01047FluocinonideSmoothened homologtarget
DB01047FluocinonideCytochrome P450 3A4enzyme
DB14512Mometasone furoateGlucocorticoid receptortarget
DB14512Mometasone furoateCytochrome P450 2C8enzyme
DB14512Mometasone furoateProgesterone receptortarget
DB14512Mometasone furoateCytochrome P450 3A4enzyme
DB01183NaloxoneMu-type opioid receptortarget
DB01183NaloxoneEstrogen receptor alphatarget
DB01183NaloxoneCyclic AMP-responsive element-binding protein 1target
DB01183NaloxoneDelta-type opioid receptortarget
DB01183NaloxoneSolute carrier organic anion transporter family member 1A2transporter
DB01183NaloxoneMultidrug resistance protein 1transporter
DB01183NaloxoneKappa-type opioid receptortarget
DB01183NaloxoneCytochrome P450 2C8enzyme
DB01183NaloxoneCytochrome P450 3A4enzyme
DB01183NaloxoneSerum albumincarrier
DB01183NaloxoneToll-like receptor 4target
DB01183NaloxoneLiver carboxylesterase 1target
DB01183NaloxoneUDP-glucuronosyltransferase 1-1enzyme
DB11614RupatadineCytochrome P450 3A4enzyme
DB11614RupatadineCytochrome P450 2C9enzyme
DB11614RupatadineCytochrome P450 2C19enzyme
DB11614RupatadineCytochrome P450 2D6enzyme
DB11614RupatadinePlatelet-activating factor receptortarget
DB11614RupatadineHistamine H1 receptortarget
DB00596UlobetasolCorticosteroid-binding globulincarrier
DB00596UlobetasolGlucocorticoid receptortarget
DrugDrug NamePhaseStatusCount
DB12154Itacitinib2Withdrawn1
DB00844Nalbuphine3Completed1
DB09495Avobenzone4Completed1
DB01744Camphor4Completed1
DB00153Ergocalciferol4Completed1
DB00825Levomenthol4Completed1
DB09535Octocrylene4Completed1
DB09345Pramocaine4Completed1
DB08604Triclosan4Completed1